| My Account | Subscribe | Contact Us | Donate |
You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
If you are a physician, educator and medical professional who focus on the treatment of diabetes, then this is the must have resource for you.
Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.
Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.
Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.
Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.
As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!
You can cancel your newsletter subscription at anytime by clicking "Unsubscribe" on the bottom of any newsletter you receive
Then enter your new email address in the above form and click "Subscribe"
Latest A1c Test Articles
Terbutaline, which goes under the trade names Brethine, Bricanyl, and Brethaire, is typically used as a fast-acting bronchodilator in asthma patients. Doctors also use it to delay premature labor. More research is needed to see if it can help type 1s.
A study of the effectiveness of the drug terbutaline on controlling nighttime hypoglycemia in people with type 1 diabetes indicates that it may be a safe and useful treatment with no ill effects.
Researchers at the Washington University School of Medicine in St. Louis studied 15 type 1 patients (average A1c: 7.1%) to see if terbutaline could prevent hypoglycemic episodes during sleep without causing hyperglycemia the following morning.
(Terbutaline, which goes under the trade names Brethine, Bricanyl, and Brethaire, is typically used as a fast-acting bronchodilator in asthma patients. Doctors also use it to delay premature labor.)
Some patients were randomly assigned a dose of 2.5 mg of terbutaline each night before going to sleep. A second group received a 5 mg dose. A third group received a placebo. The patients received their respective doses at 10 p.m. on three separate nights.
The mean lowest plasma glucose concentrations at night among the groups were:
Morning plasma glucose levels were:
Although the mean figures for the 2.5 mg terbutaline group seem to be closer to the ideal, seven patients in the group reached a nadir nocturnal concentration of 70 mg/dl; six reached 60 mg/dl; and two reached 50 mg/dl in the course of the study. While three patients in the 5 mg group reached a nadir of 70 mg/dl, none in the group reached a lower level.
The researchers had previously reported on the effectiveness of a 5 mg dose of terbutaline, but were concerned that its morning plasma glucose levels were high. While the study tentatively established the effectiveness of the 2.5 mg dose, researchers have called for a much longer, more extensive trial of the drug among type 1s.
Categories: A1c Test, Low Blood Sugar, Medications, Medications Research, Type 1 Issues
Dec 29, 2008 -
Email to a Friend
Send a link to this page to your friends and colleagues.